SCHEMBL1500296

SCHEMBL1500296

Cc1nn(-c2ccccc2F)cc1Br

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.48
ADORA3 P0DMS8 2/20 0.46
NOTUM Q6P988 1/20 0.41
KCNN4 O15554 1/20 0.39
KMT2A Q03164 2/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.37
PRNP P04156 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
ALDH1A1 P00352 1/20 0.36
PDE10A Q9Y233 1/20 0.36
RAB9A P51151 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HSP90AA1 P07900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38651310 1.00 ADORA1 (0.48) ADORA1ADORA3NOTUMKCNN4KMT2A
SCHEMBL13078708 0.84 ADORA1 (0.51) ADORA1ADORA3NOTUMKMT2AHPGD
SCHEMBL16644153 0.80 GRIN2B (0.40) ADORA1ADORA3HDAC9RAB9A
SCHEMBL13079390 0.77 ADORA1 (0.46) ADORA1ADORA3NOTUMKCNN4KMT2A
SCHEMBL990008 0.77 ADORA1 (0.40) ADORA1ADORA3NOTUMKMT2AMEN1
SCHEMBL13079036 0.76 ADORA1 (0.45) ADORA1ADORA3NOTUMKMT2AHPGD
SCHEMBL1803916 0.74 NOTUM (0.52) ADORA1ADORA3NOTUMKMT2AHPGD
SCHEMBL16090355 0.74 RAB9A (0.47) ADORA1ADORA3KMT2AHPGDPOLB
SCHEMBL3737262 0.69 ADORA1 (0.55) ADORA1ADORA3NOTUMKCNN4KMT2A
SCHEMBL13078703 0.69 MAPT (0.52) ADORA1ADORA3NOTUMKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9611263-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2017-04-04 US disclosed
US-9611263-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2017-04-04 US disclosed
US-20160229845-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2016-08-11 US disclosed
US-20160229845-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2016-08-11 US disclosed
WO-2015054283-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2015-04-16 WO disclosed
US-20110160208-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-30 US disclosed
US-7902369-B2 Diaryl-substituted five-membered heterocycle derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative MSD K.K. (JP) 2007-07-26 US disclosed
EP-1726585-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160208-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE OPRK1, GRM1, GRIK1 ADORA1 625/4885ADORA3 690/4885NOTUM 4277/4885
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative OPRK1, OPRL1, GRM1 ADORA1 1001/4885ADORA3 1194/4885NOTUM 3158/4885
US-20160229845-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 ADORA1 2226/4885ADORA3 2617/4885NOTUM 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.